39 completed, 8 recruiting, 4 unknown, 2 terminated. 54 Phase 1, 15 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 54 | Completed 39, Recruiting 8, Unknown 4, Terminated 2, Withdrawn 1 |
| Phase 2 | 15 | Completed 11, Unknown 2, Recruiting 1, Withdrawn 1 |
Follow Alcohol Drinking: new trials by email Literature Review of Alcohol Drinking trials Research Report on Alcohol Drinking
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes Placebo, Semaglutide 1.0 mg, Semaglutide 2.0 mg - Alcohol Use Disorder (AUD), Obesity (BMI Equal to or >30) | Phase 1 | Recruiting | Yale University | 90 | 2026-10-01 | 2026-11-04 |
| Precision Microbiota Interventions for Senoreduction Trial Limosilactobacillus reuteri, Blueberry extract - HIV Infections, Alcohol Drinking | Phase 1 / Phase 2 | Recruiting | Louisiana State University Health Sciences Center in New Orleans | 160 | 2026-09-01 | 2026-10-29 |
| The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD) 0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline - Alcohol Use Disorder (AUD), Alcohol-Related Disorders | Phase 1 | Recruiting | Yale University | 63 | 2025-08-04 | 2026-09-10 |
| Effect of Sublingual Formulation of Dexmedetomidine Hydrochloride (HCl) (BXCL501) - Outpatient Study Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg - Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) | Phase 1 | Recruiting | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 10 | 2025-07-28 | 2026-09-21 |
| HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention) Information Motivation Behavioral and Motivational Interviewing (IMB-MI) technique - Hiv, Alcohol Drinking | Phase 1 | Recruiting | Yale University | 100 | 2025-01-15 | 2026-09-25 |
| Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers Mavoglurant - Alcohol Consumption, Heavy Drinker | Phase 1 | Recruiting | Yale University | 63 | 2024-07-01 | 2026-08-21 |
| Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge Drink β-nicotinamide Mononucleotide, Maltodextrin - Binge Drinking, Liver Injury | Phase 1 / Phase 2 | Completed | Zhejiang Chinese Medical University | 22 | 2024-05-01 | 2025-04-10 |
| Metabolic Changes in Healthy Subjects with Acute Binge Drink Vodka, water - Binge Drinking, Liver Injury | Phase 1 | Completed | Zhejiang Chinese Medical University | 40 | 2024-04-27 | 2025-01-22 |
| Spironolactone in Alcohol Use Disorder (SAUD) Placebo, Spironolactone - Alcohol Use Disorder | Phase 1 | Recruiting | National Institute on Drug Abuse (NIDA) | 20 | 2023-07-13 | 2026-10-23 |
| Non-invasive Vagal Nerve Stimulation in Alcohol Use Disorder Cervical transcutaneous vagus nerve stimulation (active comparator), Cervical transcutaneous vagus nerve stimulation (sham comparator) - Alcohol Use Disorder | Phase 1 | Completed | VA Office of Research and Development | 19 | 2022-05-02 | 2025-07-03 |
| Personalized Feedback After Alcohol Health Education for Members of Greek Life (GREEK Study) e-checkup to go, Delayed feedback booster - College Student Drinking | Phase 1 / Phase 2 | Unknown | Abby Braitman | 250 | 2022-04-06 | 2023-05-03 |
| Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg - Alcohol Use Disorder (AUD), Post Traumatic Stress Disorder (PTSD) | Phase 1 | Completed | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | 10 | 2021-11-09 | 2023-10-26 |
| Effects of Ethanol on the Pharmacokinetics of PT-150 (Formerly ORG34517) (PT150 PK Study) PT150, Beverage - Potential Treatment for Alcohol Dependence-Alcohol Interaction | Phase 1 | Completed | Pop Test Oncology LLC | 10 | 2021-11-01 | 2023-12-04 |
| Pitolisant Effects on Alcohol Self-Administration in Heavy Drinkers Pitolisant, Placebo - Alcohol Use Disorder, Alcohol Drinking | Phase 1 | Terminated | Boston Medical Center | 9 | 2021-09-13 | 2023-12-04 |
| Opioid Modulation and Neural Reward Activation in Healthy Adults Naltrexone, Placebo - Alcohol Drinking, Opioid Use, Unspecified | Phase 1 / Phase 2 | Completed | University of Colorado, Denver | 13 | 2021-05-01 | 2023-11-28 |
| The Behavioral Effects of Opioids and Alcohol Alcohol, Opioid Agonist - Opioid Use, Alcohol Drinking | Phase 1 | Completed | Sharon Walsh | 11 | 2021-03-24 | 2025-11-20 |
| Effect of Acute Alcohol Intoxication on Neural Processes During Decisions to Engage in HIV Risk Behaviors Alcohol beverage, Placebo beverage - Alcohol Consumption | Phase 1 | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | 20 | 2021-03-18 | 2026-10-26 |
| Strengths-based Linkage to Alcohol Care (SLAC) for Hazardous Drinkers in Primary Care Strengths-based linkage to alcohol care, Usual care - Alcohol-induced Disorders, Alcohol Drinking | Phase 1 | Completed | VA Office of Research and Development | 140 | 2021-01-01 | 2026-01-13 |
| Timing Personalized Feedback After Alcohol Health Education e-checkup to go, Feedback booster - College Student Drinking | Phase 1 / Phase 2 | Completed | Abby Braitman | 195 | 2020-11-30 | 2023-05-03 |
| Neuroimmune Dysfunction in Alcohol Use Disorder Minocycline, Sugar pill - Alcohol Drinking, Alcohol-Related Disorders | Phase 1 | Completed | University of Maryland, Baltimore | 142 | 2020-02-03 | 2023-12-01 |
Showing 20 of 54. Sign in to see all of them.
Alcoholism (19) · Alcohol-Related Disorders (6) · Alcohol Drinking in College (5) · Binge Drinking (4) · Alcoholic Intoxication (3) · Drinking Behavior (3) · HIV Infections (3) · Stress Disorders, Post-Traumatic (3) · Anxiety Disorders (2) · Cognition Disorders (2) · Depression (2) · Fatty Liver (2) · Inflammation (2) · Pain (2)
Behavior (54) · Drinking Behavior (51) · Chemically-Induced Disorders (26) · Mental Disorders (26) · Substance-Related Disorders (25) · Alcohol-Related Disorders (19) · Pathological Conditions, Signs and Symptoms (6) · Blood-Borne Infections (4) · Communicable Diseases (4) · Genital Diseases (4) · Immune System Diseases (4) · Immunologic Deficiency Syndromes (4) · Infections (4) · Lentivirus Infections (4)
Ethanol (12) · Naltrexone (5) · Sugars (3) · (11R,13S,17S)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-13-methyl-17-prop-1-ynyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta(a)phenanthren-3-one (2) · Beverages (2) · Crisis Intervention (2) · Dexmedetomidine (2) · Minocycline (2) · Motivational Interviewing (2) · Organization and Administration (2) · Varenicline (2) · mavoglurant (2) · Analgesics, Opioid (1) · Baclofen (1) · Behavior Therapy (1)
Yale University (8) · Abby Braitman (5) · Boston Medical Center (4) · Brown University (4) · National Institute on Alcohol Abuse and Alcoholism (NIAAA) (4) · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance (2) · Pop Test Oncology LLC (2) · Syracuse University (2) · University of Cincinnati (2) · VA Office of Research and Development (2) · Zhejiang Chinese Medical University (2) · Battelle Memorial Institute (1) · Boston Children's Hospital (1) · Boston University (1) · Louisiana State University Health Sciences Center in New Orleans (1)
United States (44) · China (2) · Kenya (2) · Finland (1) · Russia (1) · Spain (1)
Abby L Braitman, Ph.D. (5) · Eric Devine, PhD (3) · Giao Q. Tran, Ph.D. (2) · Ismene Petrakis, MD (2) · Lorenzo Leggio, M.D. (2) · Vijay A Ramchandani, Ph.D. (2) · Amy C Justice, MD, PhD (1) · Anahita Bassir Nia, MD (1) · Anthony Spirito, Ph.D. (1) · Brian E. Borsari, PhD (1) · Christopher Verrico, PhD (1) · David A Welsh, MD (1) · Francina Fonseca, MD, PhD (1)
PMID 28351364, PMID 17574344, PMID 18612578, PMID 18781243, PMID 20116962, PMID 21134017, PMID 21193284, PMID 21631622, PMID 22924334, PMID 24512944, PMID 26098125, PMID 26402350, PMID 26460571, PMID 27062270, PMID 27621150, PMID 27936818, PMID 31399255, PMID 31557492, PMID 33155163, PMID 33607509, PMID 33682527, PMID 33972573, PMID 34081487, PMID 34238628, PMID 34766785, PMID 36306162, PMID 36480413, PMID 37530456, PMID 37592359, PMID 38100057, PMID 40483726
K01AA023849 (4), P50AA012870 (3), K01AA026005 (2), F32AA021310 (1), K23AA020000 (1), P01AA029545 (1), R01AA015708 (1), R01AA020705 (1), R01AA021818 (1), R01AA022301 (1), R01AA024844 (1), R01AA032779 (1), R01DA016718 (1), R21AA016884 (1), R21AA017291 (1)